CSIMarket Company Name, Ticker, Industry, else..
 
Polypid Ltd  (NASDAQ: PYPD)
 
Price: $5.1600 $-0.04 -0.769%
Day's High: $5.3815999031066895 Week Perf: -2.09 %
Day's Low: $ 5.16 30 Day Perf: 9.32 %
Volume (M): 25,055 52 Wk High: $ 5.73
Volume (M$): $ 0 52 Wk Avg: $4.32
Open: $5.20 52 Wk Low: $3.06



 Market Capitalization (Millions $) 66
 Shares Outstanding (Millions) 13
 Employees 59
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 19
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Business Description


Polypid Ltd is a biopharmaceutical company that specializes in developing and commercializing novel drugs for the prevention and treatment of infectious diseases. The company's focus is on creating innovative, long-acting antibiotic therapies that help overcome antimicrobial resistance and improve patient outcomes. Polypid's proprietary technology platform, known as PolyPid Controlled Release System, allows for the controlled release of drugs at specific target sites, ensuring a prolonged and effective therapy. Their product pipeline includes potential treatments for a range of bacterial infections, including surgical site infections and chronic osteomyelitis. Polypid is dedicated to addressing the global healthcare challenge of drug-resistant infections and improving the quality of life for patients.


   Company Address: 18 Hasivim Street Petach Tikva 495376 NJ
   Company Phone Number: 858-5995   Stock Exchange / Ticker: NASDAQ PYPD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

In a groundbreaking move set to push the boundaries of modern cancer treatment, PolyPid Ltd. and ImmunoGene...

Published Mon, Dec 30 2024 2:06 AM UTC

Transforming Cancer Treatment: PolyPid and ImmunoGenesis Join Forces to Revolutionize Immunotherapy with PLEX Technology In a groundbreaking move set to push the boundaries of modern cancer treatment, PolyPid Ltd. and ImmunoGenesis, Inc. have announced an innovative research and development collaboration aimed at enhancing cancer immunotherapy. By leveraging PolyPid’s cutt...
Clinical Study

Pioneering Pathways PolyPids D-PLEX Phase 3 SHIELD II Trial Poised for Transformational Impact

Published Tue, Dec 24 2024 12:22 AM UTC

PolyPid s Momentum in Antimicrobial Innovations: Unveiling the SHIELD II Phase 3 Trial The recent announcement by PolyPid marks a significant stride in the arena of antimicrobial therapies with the Data and Safety Monitoring Board s (DSMB) favorable recommendation to continue enrolling patients in the Phase 3 SHIELD II trial. The trial focuses on D-PLEX100, an innovative loc...
Stock Market Announcement

PolyPid Ltd. Faces Nasdaq Compliance Challenge Amid Advanced R&D Milestones

Published Fri, Nov 29 2024 6:05 PM UTC

PolyPid Ltd. Navigates Compliance Hurdle While Advancing Pioneering TrialsPETACH TIKVA, Israel, Nov. 29, 2024 PolyPid Ltd. (Nasdaq: PYPD), a distinguished late-stage biopharmaceutical company committed to enhancing surgical outcomes, finds itself at a pivotal moment. While the company is breaking new ground with promising developments in its phase 3 clinical trials, it mus...
Clinical Study

Evolving Infection Prevention PolyPids D-PLEX Progresses in Phase 3 SHIELD II Trial for Colorectal Surgerie...

Published Tue, Oct 1 2024 11:00 AM UTC

Surgical site infections (SSIs) represent a significant challenge in the landscape of post-operative care, particularly following abdominal colorectal surgeries. These infections not only contribute to increased morbidity and extended hospital stays but also place a considerable financial burden on healthcare systems worldwide. In an era where precise surgical outcomes are m...
Financing Agreement

PolyPid Secures Funding and Achieves High Leverage Ratio, Bolstering Outlook for SHIELD II Trial Results

Published Fri, Aug 2 2024 12:31 AM UTC

PolyPid Secures Funding to Extend Cash Runway and Achieves High Leverage Ratio
PETACH TIKVA, Israel - In a recent press release, PolyPid Ltd. (Nasdaq: PYPD) has announced that it has successfully secured funding that will extend the company s cash runway into the second quarter of 2025. This funding comes at a crucial moment for PolyPid as it aligns with the anticipated ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.74
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 6.04
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.93
Working Capital Ratio 4.29
Leverage Ratio (MRQ) 1.33
Total Debt to Equity 0.77
Interest Coverage (TTM) -
Debt Coverage (TTM) 1.63

Per Share Current
Earnings (TTM) 6.94 $
Revenues (TTM) -
Cash Flow (TTM) 0.79 $
Cash 1.02 $
Book Value 0.85 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 322,797
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) 0.1 %

Management Effectiveness Current
Return On Assets (TTM) 30.01 %
Return On Investment (TTM) 118.74 %
Return On Equity (TTM) 162.72 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.